July 22 (Reuters) - BioLife Solutions Inc BLFS.O:

• REPLIGEN TO ACQUIRE BIOLIFE SOLUTIONS, EXPANDING ITS CELL THERAPY CAPABILITIES WITH MARKET LEADING BIOPRESERVATION MEDIA

• BIOLIFE SOLUTIONS - REPLIGEN TO BUY BIOLIFE FOR $1.50 BILLION ENTERPRISE VALUE, 64% STOCK, 36% CASH

• BIOLIFE SOLUTIONS - STOCKHOLDERS TO RECEIVE $31 PER SHARE IN CASH AND REPLIGEN STOCK

• BIOLIFE SOLUTIONS - DEAL EXPECTED TO BE ACCRETIVE TO REPLIGEN'S ADJUSTED EPS BY $0.05 IN YEAR ONE, $0.25 IN YEAR TWO

• BIOLIFE SOLUTIONS - STOCKHOLDERS TO RECEIVE $11.25 CASH AND 0.1442 REPLIGEN SHARES PER BIOLIFE SHARE

• BIOLIFE SOLUTIONS - REPLIGEN EXPECTS AT LEAST $20 MILLION SYNERGIES IN YEAR ONE, $30 MILLION IN YEAR TWO

• BIOLIFE SOLUTIONS - EXPECTS PRELIMINARY Q2 REVENUE OF $28.50 MILLION, UP 21% FROM Q2 2025

• BIOLIFE SOLUTIONS - REPLIGEN PRELIMINARY Q2 REPORTED REVENUE GROWTH 12%, ORGANIC REVENUE GROWTH 13%

• BIOLIFE SOLUTIONS - PRELIMINARY Q2 REVENUE GROWTH 21% YEAR-OVER-YEAR

Source text: ID:nGNXbFRqpW

Further company coverage: BLFS.O